Previously, preclinical studies have suggested that heregulin may cause resistance to first-generation EGFR-TKIs such as erlotinib in NSCLC patients harboring EGFR-activating mutations, as heregulin promotes HER2-HER3 coupling and activates anti-apoptotic HER2-HER3-Akt bypass signaling27. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.